oncology research

BRCR Global is a clinical research organization founded in 2009 and headquartered in Weston, FL. It connects sites, investigators, patients, and sponsors through a clinical research platform supporting Phase I to Phase IV clinical trial implementation across the Americas and Caribbean, with a site network including locations in Puerto Rico (Mayagüez, San Juan, Ponce, Yauco).

clinical operationsclinical trial implementationData OperationsGCP-compliant study executionpatient recruitmentregulatory supportstudy start-up

Day One Biopharmaceuticals is a biopharmaceutical company focused on advancing first- or best-in-class targeted medicines for childhood and adult diseases, particularly cancer. Founded to address the lack of new therapies from the traditional drug development model, it develops new medicines for people of all ages with life-threatening diseases. The company is now part of Servier Group and is based in Brisbane, California.

clinical trialsdrug development

Empyrean Medical Systems is a Boca Raton, Florida company established in 2020 dedicated to transforming cancer treatment. Its expertise spans a research and clinical devices division and an informatics division, with additional therapeutics and informatics divisions, integrating quantum physics, molecular biology, chemistry, and machine learning to offer accuracy and safety in cancer treatment and research.

machine learningmedical device developmentparticle physics research

Flatiron Health transforms oncology by leveraging real-world data and AI to provide actionable insights, improving patient outcomes and advancing cancer research globally. Its global oncology engine captures data from millions of cancer patients around the world directly at the source and transforms it into actionable insights across the oncology ecosystem. Flatiron real-world data has informed 2,000+ publications.

AI-powered analyticsreal-world data capture

iOnctura is a clinical-stage biotechnology company developing precision medicines for cancer and other challenging diseases. Founded in 2017, it develops high impact, low disruption therapies targeting the tumor-stroma-immune interface, focusing on neglected and hard to treat cancers with more effective, less toxic treatments.

clinical developmentdrug developmentsmall molecule drug discovery